Search results
Results from the WOW.Com Content Network
The cost of Rituxan can depend on factors such as where a person lives and the facility that they visit to receive the infusions. If a person has Original Medicare, they will need to pay the Part ...
Rituximab, sold under the brand name Rituxan among others, is a monoclonal antibody medication used to treat certain autoimmune diseases and types of cancer. [18] It is used for non-Hodgkin lymphoma, chronic lymphocytic leukemia (in children and adults, but not recommended in elderly patients), rheumatoid arthritis, granulomatosis with polyangiitis, idiopathic thrombocytopenic purpura ...
Drug Dose Mode Days Rituximab: 375 mg/m 2: IV infusion: Day 1 Ifosfamide: 5000 mg/m 2: IV continuous infusion over 24 hours: Day 2 Mesna for haemorrhagic cystitis prophylaxis with ifosfamide
The treatment starts with an infusion of rituximab. This may be followed by an administration of indium-111 labeled ibritumomab tiuxetan (111 In replaces the 90 Y component) to allow the distribution of the medication to be imaged on a gamma camera, before the actual therapy is administered. [6]
Rituximab: 375 mg/m 2: IV infusion: Day 1 Etoposide: 50 mg/m 2: IV continuous infusion over 24 h: Days 1–4 Prednisolone: 60 mg/m 2: By mouth, twice a day (PO BID) Days 1–5 Oncovin: vincristine: 0.4 mg/m 2: IV continuous infusion over 24 h: Days 1–4 Cyclophosphamide: 750 mg/m 2: IV bolus given over 15 min: Day 5 Hydroxydaunorubicin ...
This regimen can also be combined with the monoclonal antibody rituximab if the lymphoma is of B cell origin; this combination is called R-CHOP. In 2002, a randomized controlled trial showed a higher complete response rate for R-CHOP vs CHOP in elderly patients with Diffuse Large-B-Cell Lymphoma (76% vs 63%). [ 4 ]
Rituximab: Rituxan, Mabthera chimeric CD20: 1997 non-Hodgkin lymphoma [67] Rituximab/hyaluronidase: Rituxan Hycela chimeric CD20: 2017 follicular lymphoma, diffuse large B-cell lymphoma, chronic lymphocytic leukemia [68] Trastuzumab: Rituxan Hycela humanized HER2/neu: 1998 breast cancer, gastric or gastroesophageal junction adenocarcinoma
R-HDAC, or R-HD-AraC (ituximab plus (H)igh (D)ose ra-) is a chemotherapy regimen that is used, alternating with R-Maxi-CHOP, as part of so-called "Nordic protocol" of treating mantle cell lymphoma.